Poly(3-Hydroxybutyrate)-Based Nanoparticles for Sorafenib and Doxorubicin Anticancer Drug Delivery

Autor: Andrea Fodor-Kardos, Joanna Rydz, Magdalena Klim, Tivadar Feczkó, Michał Kawalec, György Babos, László Trif
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Drug
Sorafenib
media_common.quotation_subject
Nanoparticle
02 engineering and technology
poly(3-hydroxybutyrate)
010402 general chemistry
01 natural sciences
doxorubicin
Article
Catalysis
Polyethylene Glycols
lcsh:Chemistry
Inorganic Chemistry
chemistry.chemical_compound
Drug Delivery Systems
Polylactic Acid-Polyglycolic Acid Copolymer
dual drug-loaded nanoparticles
Prohibitins
PEG ratio
medicine
Humans
Doxorubicin
Physical and Theoretical Chemistry
lcsh:QH301-705.5
Molecular Biology
Spectroscopy
media_common
Drug Carriers
Organic Chemistry
technology
industry
and agriculture
General Medicine
HCT116 Cells
021001 nanoscience & nanotechnology
0104 chemical sciences
Computer Science Applications
lcsh:Biology (General)
lcsh:QD1-999
chemistry
PEGylation
Biophysics
Nanoparticles
sorafenib
Nanocarriers
Colorectal Neoplasms
0210 nano-technology
Ethylene glycol
medicine.drug
Zdroj: International Journal of Molecular Sciences
Volume 21
Issue 19
International Journal of Molecular Sciences, Vol 21, Iss 7312, p 7312 (2020)
ISSN: 1422-0067
DOI: 10.3390/ijms21197312
Popis: Dual drug-loaded nanotherapeutics can play an important role against the drug resistance and side effects of the single drugs. Doxorubicin and sorafenib were efficiently co-encapsulated by tailor-made poly([R,S]-3-hydroxybutyrate) (PHB) using an emulsion&ndash
solvent evaporation method. Subsequent poly(ethylene glycol) (PEG) conjugation onto nanoparticles was applied to make the nanocarriers stealth and to improve their drug release characteristics. Monodisperse PHB&ndash
sorafenib&ndash
doxorubicin nanoparticles had an average size of 199.3 nm, which was increased to 250.5 nm after PEGylation. The nanoparticle yield and encapsulation efficiencies of drugs decreased slightly in consequence of PEG conjugation. The drug release of the doxorubicin was beneficial, since it was liberated faster in a tumor-specific acidic environment than in blood plasma. The PEG attachment decelerated the release of both the doxorubicin and the sorafenib, however, the release of the latter drug remained still significantly faster with increased initial burst compared to doxorubicin. Nevertheless, the PEG&ndash
PHB copolymer showed more beneficial drug release kinetics in vitro in comparison with our recently developed PEGylated poly(lactic-co-glycolic acid) nanoparticles loaded with the same drugs.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje